Stock Market Reviews

GLUE (Monte Rosa Therapeutics, Inc.) News

Get the latest news, insights, and market updates on GLUE (Monte Rosa Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
  Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 underway, investigating a potential novel approach to treat inflammatory diseases driven by the NLRP3 inflammasome; initial readout including data from high-CVD risk cohort on track for H1 2026 VAV1-directe
  Nov 6, 2025 - $GLUE
• Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
  Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +150.00% and +0.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $GLUE
• Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
  BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) – November 10, 2025, at 11:30 a.m. ETTD Cowen Immunology & Inflammation Summit (virtual) – November
  Nov 3, 2025 - $GLUE
• Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
  Most readers would already be aware that Monte Rosa Therapeutics' (NASDAQ:GLUE) stock increased significantly by 123...
  Oct 29, 2025 - $GLUE
• Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
  MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren’s disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics
  Oct 24, 2025 - $GLUE
• Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects
  Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is among the best fast money stocks to buy now. During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 13,182 shares of the company’s stock. According to the latest filing with the SEC, the firm’s investment in the […]
  Sep 30, 2025 - $GLUE
• Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
  GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
  Sep 16, 2025 - $GLUE
• Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
  Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
  Sep 16, 2025 - $GLUE
• Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics
  Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion. Shares of Monte Rosa surged 65% in premarket trading after the announcement.
  Sep 15, 2025 - $GLUE
• Traders Cautious Ahead of Fed Meeting, Driving Muted Premarket Action for US Equity Futures
  US equity futures were flat before Monday's opening bell as traders remained on the sidelines ahead
  Sep 15, 2025 - $GLUE